ABUS vs ZBIO Stock Comparison

ABUS currently leads ZBIO in this stock comparison, with AIQ scores of 70 vs 47. The clearest difference is value, while ZBIO has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 23 points
ABUS
Healthcare
vs
ZBIO
Healthcare
ABUS
Arbutus Biopharma Corp
Leads
Price
$4.09
Day move
+1.49%
AIQ Score
70/100
Best edge
Value
Sector
Healthcare
ZBIO
Zenas BioPharma, Inc.
Price
$28.01
Day move
+1.34%
AIQ Score
47/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between ABUS and ZBIO?

ABUS leads the current stock comparison as Arbutus Biopharma Corp, with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Arbutus Biopharma Corp vs Zenas BioPharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 61/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 8/10

ABUS leads

ABUS leads by 23 AIQ points, primarily on Value and Quality.

Competitive: 4 of 5 evidence groups support ABUS, and its current signal state is conflicted.

Evidence agreement: 4 of 5Comparison trend: Stable
ABUS

Arbutus Biopharma Corp

Leads
AIQ Score
70/100
AIQ Edge Score
9/10
ZBIO

Zenas BioPharma, Inc.

AIQ Score
47/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors ABUS over ZBIO, 70 versus 47 as of Nov 15, 2026. ABUS's advantage is driven primarily by stronger value and quality, while ZBIO holds the stronger momentum profile. ABUS also shows the weaker technical structure relative to its 50-day moving average. 4 of 5 covered evidence groups favor ABUS today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. ABUS lead: Stable — the AIQ differential has held near 23 points over 30 sessions.

Compare Arbutus Biopharma Corp and Zenas BioPharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ABUS
-8.5%
ZBIO
+54.3%

Price return comparison

Growth of $10,000, price only

ABUS $9,150 · ZBIO $15,433

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ABUS and ZBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABUS advantage
0
ZBIO advantage
  • Value92 vs 33
    ABUS +59
  • Quality82 vs 25
    ABUS +57
  • Momentum51 vs 78
    ZBIO +27
  • Risk Resilience62 vs 39
    ABUS +23

4 of 5 evidence groups favor ABUS. ABUS’s edge is concentrated in value and quality; ZBIO keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ABUS0 AIQ

No factor moved materially.

New signals

  • Death Cross Active — bearish, trend, long horizon (0.45%)
  • Downtrend Structure Active — bearish, trend, long horizon
ZBIO+1 AIQ

Largest factor move: Momentum +2

New signals

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

ABUS's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — ABUS and ZBIO both carry a full feed there.

The central trade-off

ABUS (Arbutus Biopharma Corp): the stronger current systematic profile, led by value and quality.

ZBIO (Zenas BioPharma, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 65.7% against 52.1%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ABUS

ABUS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ZBIO

ZBIO on combined revenue and EPS growth.

Value

ABUS

ABUS on the peer-relative Value factor, by 59 points.

Momentum

ZBIO

ZBIO on the Momentum factor, by 27 points.

Lower downside

ABUS

ABUS on Risk Resilience, by 23 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureABUSZBIONote
Implied upside to target—+96.4%Level
Target dispersion—0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering18Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 5 covered evidence groups favor ABUS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreABUS70 vs 47
FundamentalsABUSon balancerevenue growth -70.5% vs 9%; EPS growth 11% vs 6.8%; TTM ROE 68.9% vs -51.3%; gross margin 100% vs -6.6%; operating margin 79.9% vs -47.9% — ABUS takes 4 of 5 decided legs, not all of them
ValuationABUSValue 92 vs 33
TechnicalsZBIOPrice vs 50-day -8.3% vs -2%; vs 200-day -8.7% vs 10.5%
Risk ResilienceABUSRisk Resilience 62 vs 39
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABUS and ZBIO and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 23 points. (supports the conclusion holding)
  • 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ABUS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ABUS lead: Stable — the AIQ differential has held near 23 points over 30 sessions.

May 27ABUS leads above the line · ZBIO leads belowNov 13
Today
ABUS +23
70 vs 47
7 sessions ago
ABUS +22
68 vs 46
30 sessions ago
ABUS +25
68 vs 43
90 sessions ago
ABUS +27
72 vs 45

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABUSConflicted

2 bullish / 3 bearish / 1 neutral, conflicted

Only ABUS

  • Death Cross Active — bearish, trend, long horizon (0.45%)
  • Distribution Pattern — bearish, volume, medium horizon (1.36x)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
ZBIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only ZBIO

  • Golden Cross Active — bullish, trend, long horizon (12.78%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

ABUS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABUSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.49%, AIQ 0 points).

ZBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.34%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ZBIO closes the Value gap — currently 59 points behind, the largest single contributor to ABUS's edge.
  2. 2ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ABUS leads on balance
MetricABUSZBIO
Revenue growth (YoY)-70.5%9%
EPS growth (YoY)11%6.8%
Gross margin100%-6.6%
Operating margin79.9%-47.9%
Return on equity (TTM)68.9%-51.3%
Debt to equity01.42

Performance

Split across windows
MetricABUSZBIO
1 week (5 sessions)11.9%-0.9%
1 month (20 sessions)-3.1%12.8%
3 months (63 sessions)-13.2%-8.2%
6 months (126 sessions)-3.5%52.7%
Year to date-15%-22.9%
1 year (252 sessions)-15.5%-21.8%

Technicals

ZBIO has the stronger structure
MetricABUSZBIO
RSI (14)48.550.1
ADX (14)29.212.2
Price vs 50-day-8.3%-2%
Price vs 200-day-8.7%10.5%
Volatility (1M, annualized)52.1%65.7%

Risk

ABUS is the more resilient
MetricABUSZBIO
Beta1.190.75
Sharpe ratio-0.090.26
Sortino ratio-0.130.34
Max drawdown-30%-64.8%
Current drawdown-21.6%-35.1%
Annualized volatility45.9%95.3%
Value at risk (95%)-4.4%-7.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABUS or ZBIO?

On the Algovestiq AIQ Score, ABUS is the stronger of the two as of Nov 15, 2026, scoring 70 against ZBIO's 47. The edge comes from value and quality. ZBIO is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABUS or ZBIO the better buy right now?

ABUS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor ABUS over ZBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. ABUS leads Value by 59 points; ABUS leads Quality by 57 points; ZBIO leads Momentum by 27 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABUS or ZBIO?

Analyst price targets imply not covered upside for ABUS and +96.4% for ZBIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABUS or ZBIO?

ABUS is the better-valued of the two on the peer-relative Value factor. ABUS on the peer-relative Value factor, by 59 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABUS or ZBIO?

ZBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABUS or ZBIO?

ZBIO on the Momentum factor, by 27 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABUS or ZBIO?

ABUS is the more resilient of the two, so the other name carries the higher downside risk. ABUS on Risk Resilience, by 23 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABUS more profitable than ZBIO?

ABUS leads on the comparable margin measures — gross margin 100% vs -6.6%; operating margin 79.9% vs -47.9%; ttm roe 68.9% vs -51.3%.

Is ABUS's lead over ZBIO getting stronger or weaker?

ABUS lead: Stable — the AIQ differential has held near 23 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the ABUS vs ZBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZBIO closes the Value gap — currently 59 points behind, the largest single contributor to ABUS's edge; ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about ABUS and ZBIO?

ABUS: 2 bullish / 3 bearish / 1 neutral, conflicted. ZBIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABUS is Death Cross Active (bearish, long horizon). On ZBIO it is Golden Cross Active (bullish, long horizon).

Compare ABUS and ZBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.